143 related articles for article (PubMed ID: 18537725)
21. Anti-diabetic and anti-inflammatory effect of a novel selective 11β-HSD1 inhibitor in the diet-induced obese mice.
Park SB; Jung WH; Kang NS; Park JS; Bae GH; Kim HY; Rhee SD; Kang SK; Ahn JH; Jeong HG; Kim KY
Eur J Pharmacol; 2013 Dec; 721(1-3):70-9. PubMed ID: 24135201
[TBL] [Abstract][Full Text] [Related]
22. The role of 11beta-hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11beta-hsd1 inhibitors.
Saiah E
Curr Med Chem; 2008; 15(7):642-9. PubMed ID: 18336279
[TBL] [Abstract][Full Text] [Related]
23. Discovery of novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 by docking and pharmacophore modeling.
Yang H; Dou W; Lou J; Leng Y; Shen J
Bioorg Med Chem Lett; 2008 Feb; 18(4):1340-5. PubMed ID: 18242087
[TBL] [Abstract][Full Text] [Related]
24. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
25. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in type 2 diabetes mellitus.
Hollis G; Huber R
Diabetes Obes Metab; 2011 Jan; 13(1):1-6. PubMed ID: 21114597
[TBL] [Abstract][Full Text] [Related]
26. A novel highly potent and selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, INU-101.
Hong SP; Han D; Chang KH; Ahn SK
Eur J Pharmacol; 2018 Sep; 835():169-178. PubMed ID: 30096297
[TBL] [Abstract][Full Text] [Related]
27. INCB-13739, an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor for the treatment of type 2 diabetes.
Tiwari A
IDrugs; 2010 Apr; 13(4):266-75. PubMed ID: 20373256
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of novel curcumin analogues for inhibition of 11β-hydroxysteroid dehydrogenase type 1 with anti-diabetic properties.
Yuan X; Li H; Bai H; Su Z; Xiang Q; Wang C; Zhao B; Zhang Y; Zhang Q; Chu Y; Huang Y
Eur J Med Chem; 2014 Apr; 77():223-30. PubMed ID: 24642565
[TBL] [Abstract][Full Text] [Related]
29. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
30. Momordica charantia extract, a herbal remedy for type 2 diabetes, contains a specific 11β-hydroxysteroid dehydrogenase type 1 inhibitor.
Blum A; Loerz C; Martin HJ; Staab-Weijnitz CA; Maser E
J Steroid Biochem Mol Biol; 2012 Jan; 128(1-2):51-5. PubMed ID: 22001161
[TBL] [Abstract][Full Text] [Related]
31. Azabicyclic sulfonamides as potent 11beta-HSD1 inhibitors.
Shah U; Boyle CD; Chackalamannil S; Baker H; Kowalski T; Lee J; Terracina G; Zhang L
Bioorg Med Chem Lett; 2010 Mar; 20(5):1551-4. PubMed ID: 20149650
[TBL] [Abstract][Full Text] [Related]
32. Identification of novel 11β-HSD1 inhibitors by combined ligand- and structure-based virtual screening.
Lagos CF; Vecchiola A; Allende F; Fuentes CA; Tichauer JE; Valdivia C; Solari S; Campino C; Tapia-Castillo A; Baudrand R; Villarroel P; Cifuentes M; Owen GI; Carvajal CA; Fardella CE
Mol Cell Endocrinol; 2014 Mar; 384(1-2):71-82. PubMed ID: 24447464
[TBL] [Abstract][Full Text] [Related]
33. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
Hult M; Shafqat N; Elleby B; Mitschke D; Svensson S; Forsgren M; Barf T; Vallgårda J; Abrahmsen L; Oppermann U
Mol Cell Endocrinol; 2006 Mar; 248(1-2):26-33. PubMed ID: 16431016
[TBL] [Abstract][Full Text] [Related]
34. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
[TBL] [Abstract][Full Text] [Related]
35. 11β-HSD1 inhibitors for the treatment of type 2 diabetes and cardiovascular disease.
Anderson A; Walker BR
Drugs; 2013 Sep; 73(13):1385-93. PubMed ID: 23990334
[TBL] [Abstract][Full Text] [Related]
36. Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.
Su X; Vicker N; Ganeshapillai D; Smith A; Purohit A; Reed MJ; Potter BV
Mol Cell Endocrinol; 2006 Mar; 248(1-2):214-7. PubMed ID: 16325333
[TBL] [Abstract][Full Text] [Related]
37. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: a review of recent patents.
Boyle CD; Kowalski TJ
Expert Opin Ther Pat; 2009 Jun; 19(6):801-25. PubMed ID: 19456274
[TBL] [Abstract][Full Text] [Related]
38. Exploring N-acyl-4-azatetracyclo[5.3.2.0
Leiva R; McBride A; Binnie M; Webster SP; Vázquez S
Molecules; 2018 Feb; 23(3):. PubMed ID: 29495550
[TBL] [Abstract][Full Text] [Related]
39. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
Johansson L; Fotsch C; Bartberger MD; Castro VM; Chen M; Emery M; Gustafsson S; Hale C; Hickman D; Homan E; Jordan SR; Komorowski R; Li A; McRae K; Moniz G; Matsumoto G; Orihuela C; Palm G; Veniant M; Wang M; Williams M; Zhang J
J Med Chem; 2008 May; 51(10):2933-43. PubMed ID: 18419108
[TBL] [Abstract][Full Text] [Related]
40. The development and SAR of pyrrolidine carboxamide 11beta-HSD1 inhibitors.
Cheng H; Hoffman J; Le P; Nair SK; Cripps S; Matthews J; Smith C; Yang M; Kupchinsky S; Dress K; Edwards M; Cole B; Walters E; Loh C; Ermolieff J; Fanjul A; Bhat GB; Herrera J; Pauly T; Hosea N; Paderes G; Rejto P
Bioorg Med Chem Lett; 2010 May; 20(9):2897-902. PubMed ID: 20363126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]